Paige Digital Diagnostics

Paige Prostate (FDA and CE-IVD) and Breast (CE-IVD) Digital Diagnostics are delivered through the FDA-cleared & CE-marked FullFocusTM viewer provides pathologists with AI-powered workflows to increase throughput and turnaround time, with greater confidence and accuracy.
Paige Platform
A comprehensive enterprise imaging solution that is inclusive of viewer, storage capabilities, and digital diagnostics and is compatible with existing digital pathology solutions, including most scanners, monitors, and laboratory information systems.
Anywhere, Anytime Access with Full Focus™
FullFocus is an intuitive, responsive, FDA-cleared, CE-marked viewer for primary diagnosis. FullFocus is designed for pathologists to further leverage computational pathology products as they become available for clinical use.

Benefits
- A pathologist-centric user experience.
- Fast performance to load and view digital slides.
- Access to digital slides for multiple users from any internet-enabled location.*
- Ready to deliver computational pathology products.
- Secure, scalable, and highly available storage.
- Cost-effective and with no upfront capital expenses.
- Fast to deploy and minimal ongoing maintenance needs.
- Designed for interoperability with most scanners, monitors, and LIS
*Per CMS guidelines, remote review is possible during the COVID 19 Public Health Emergency
Digital Diagnostics
Paige offers two diagnostic tools for Breast Cancer (CE-IVD) and Prostate Cancer Detection (FDA and CE-IVD) that aim to provide pathologists with AI-powered workflows to increase the number of cases that can be reviewed in the same time, with greater confidence and accuracy.
Digital Diagnostic
Paige Prostate Clinical (FDA & CE-IVD)
A prostate cancer solution that detects, grades and quantifies areas suspicious for cancer.

Digital Diagnostic
Paige Breast Clinical (CE-IVD)
A breast cancer solution that detects areas suspicious for cancer.

| Solution Type | AI Suite/Add-on |
|---|---|
| Deployment Environment | Clinical Diagnostics |
| Regulatory Clearance | Breast Cancer – CE-IVD, Prostate Cancer – CE-IVD, Prostate Cancer – FDA Cleared |
| Target | Breast Cancer, Prostate Cancer |
| Platform Dependency | Requires Specific Platform |
| Deployment Options | Cloud-Based (SaaS) |
More Solutions from Paige
Compare Solutions
Get Pathology News Delivered to Your Inbox
Learn More
Paige News
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Editor2026-07-21T15:31:16+00:00July 17, 2026|
Tempus AI, Inc.: A Bull Case Theory
Editor2026-02-24T12:10:21+00:00February 12, 2026|
Tempus AI, Inc. Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones
Editor2026-02-11T16:04:22+00:00February 10, 2026|
Firsthand Insights from the Paige–Tempus Acquisition & the Future of Newfound Capabilities
Editor2026-02-19T11:06:33+00:00February 9, 2026|
Tempus Announces the Acquisition of Paige
Editor2025-09-02T14:48:32+00:00August 23, 2025|
Paige and Oncoclínicas Strengthen Leadership in AI-Driven Cancer Diagnostics Across Brazil
Editor2025-08-05T22:01:12+00:00July 30, 2025|
Paige Releases PRISM2: A Whole-Slide Foundation Model for Multimodal AI in Pathology and Cancer Care
Editor2025-07-28T10:34:46+00:00July 21, 2025|












Reviews
There are no reviews yet.